Abstract: The purpose of the present invention is to provide an effective therapeutic pharmaceutical composition for treating pancreatic cancer. The problem can be solved by a pharmaceutical composition comprising a fibroblast growth factor receptor 4 inhibitor and a senolytic drug as active ingredients.

Abstract: The invention provides a gold-supporting catalyst comprising gold nanoparticles and a carrier consisting of porous ceramic obtained by firing a mixture comprising an aluminum compound, a lime component, and a plastic clay containing 1% by mass or less of feldspars and quartz, wherein the gold nanoparticles are supported in an amount of 0.01 to 10 parts by mass on the carrier based on 100 parts by mass of the carrier.

Abstract: A heat-resistant alloy contains Y, a content of Ni is a content of Ni is 58.0 mass % or greater, a content of Cr is 20.0 mass % or greater and 23.0 mass % or less, a content of Mo is 8.0 mass % or greater and 10.0 mass % or less, a content of Nb is 3.15 mass % or greater and 4.15 mass % or less, a content of O is 0.002 mass % or greater and 0.1 mass % or less, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

Abstract: The present invention provides a disease model animal for tauopathies which reproduces the expression pattern of tau protein isoforms of adult human brain, that is, approximately equal amounts of 3R type tau and 4R type tau being expressed in the adult brain. The method for producing the disease model animal for tauopathies of the present invention comprises the steps of: preparing a tau seeds; and injecting the tau seeds in the brain of an animal carrying a mutation in the tau gene which fails to express the tenth exon. The animal carrying a mutation in the tau gene which fails to express the tenth exon may be produced by using any of the genome editing, gene targeting or base editing technologies.

Abstract: A heat-resistant alloy contains at least one element selected from a group consisting of Al, Ti, Ni, Cr, and Mo, O, and Y, and a ratio of a content of Y in terms of mass to a content of O in terms of mass is 0.5 or greater and 100 or less.

Abstract: The object of the present invention is to provide a therapeutic agent for treating hormone therapy-resistant, treatment-resistant cancers, and a method of the treatment of hormone therapy-resistant, treatment-resistant cancers. The problem can be solved by a pharmaceutical composition including a compound represented by the formula (1) or a salt thereof or a compound represented by the formula (2) or (3) or a salt thereof, as an active ingredient for treating prostate cancer. Furthermore, the pharmaceutical composition of the present invention can effectively treat not only hormone therapy-resistant prostate cancer or breast cancer but also non-hormone therapy-resistant prostate cancer or breast cancer and Castration-resistant prostate cancer or treatment-resistant breast cancer caused by other mechanisms.

Abstract: [Problem] The purpose of the present invention is to provide a deodorizing catalyst that can decompose a malodorous substance even at a low temperature of 100° C. or less. [Solution] A deodorizing catalyst for decomposing a malodorous substance, comprising: manganese oxide wherein the manganese oxide satisfies the following expression (1) and the following expression (2), and the manganese oxide has a maximum intensity peak at a diffraction angle (2?) of 37±1° in an X-ray diffraction pattern: 0<A?0.90 . . . ??(1) 0<B?250 . . .

Abstract: An additive manufacturing method is provided for building a manufacturing object by building of repeating formation of one of a sintered portion or a fused portion by selectively heating a thinly developed powder material within a working region on the basis of drawing data derived from three-dimensional data of the manufacturing object and further formation of a new thin layer on one of the sintered portion or the fused portion. The additive manufacturing apparatus includes one or more channels connecting the inside and the outside of the region, and introduces a fluid into a crack progressing into the un-fused powder material through the channel after completion of building to forcibly cool one of the sintered portion or the fused portion, and the un-fused powder material.

Abstract: The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc. The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.

Abstract: The present invention relates to a highly oriented collagen fibril bundle having a length in a major axis direction of 1 m or more.

Abstract: The present invention aims to provide a peptide of the C region of HGS and an antitumor agent comprising the same having a higher tumor growth inhibitory effect as compared with conventional techniques. An antitumor agent comprising a peptide comprising at least 10 consecutive amino acid residues of the amino acid sequence of the C region of HGS is described.

Abstract: Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.

Abstract: A novel therapeutic agent effective for the treatment of intellectual disability or autism is disclosed. The therapeutic agent for intellectual disability or autism contains, as an active component(s), at least one selected from the group consisting of tipifarnib and lonafarnib. Examples of the intellectual disability include memory impairment. Examples of the memory impairment include memory impairment caused by abnormality of the Tsc1 gene and/or Tsc2 gene, and epilepsy-induced memory impairment. Also provided is a method of treating intellectual disability or autism, comprising administering an effective amount of at least one selected from the group consisting of tipifarnib and lonafarnib to a patient with intellectual disability or autism.

Abstract: A sound source separation program causes a computer to acquire an acoustic signal, convert the acquired acoustic signal from a time region to a frequency region, and perform sound source separation on the acoustic signal converted to the frequency region by performing updating based on elementary row operation on a demixing matrix to iteratively minimize an objective function including a quadratic form of a separation vector and a determinant of the demixing matrix.

Abstract: Modulation of neural activity in the superior laryngeal nerve (SLN) or cervical sympathetic trunk (CST) is effective in treating diseases and conditions mediated by thyroid and parathyroid hormones, in particular diseases associated with calcitonin secretion (e.g. osteoporosis) or diseases associated with thyroxine secretion (e.g. hypothyroid syndrome).

Abstract: A burner device for supplying a mixture of a fuel gas and a combustion-supporting gas into a combustion region includes: a mixing path configured to inject the mixture from a downstream end portion of the mixing path into the combustion region; a fuel gas injection nozzle configured to inject the fuel gas into the mixing path toward the combustion region; and a combustion-supporting gas supply swirler configured to inject the combustion-supporting gas such that at least a part of the combustion-supporting gas collides directly with the fuel gas injected from the fuel gas injection nozzle, in a direction of a tangent line that is tangent to a fuel injection hole of the fuel gas injection nozzle on a cross-section.

Abstract: The present invention provides a prophylactic or therapeutic composition for graft-versus-host disease (GVHD). There is provided a prophylactic or therapeutic composition for GVHD, which comprises bacteria belonging to any genus selected from the group consisting of the following genera: Blautia, Clostridium, unclassified Clostridiales, Actinomyces, Parabacteroides, Lachnoclostridium, Bacteroides, Faecalibacterium, unclassified Lachnospiraceae, Roseburia, Ruminococcus, unclassified Firmicutes, Dorea, Phascolarctobacterium, Sutterella, Megamonas, Collinsella, Eubacterium, and Coprococcus, etc., or any combination of bacteria belonging to these genera.

Abstract: Provided is a combustion system using a catalyst having better denitration efficiency at low temperatures, during a selective catalytic reduction reaction in which ammonia is used as a reducing agent. This combustion system comprises: a combustion device that combusts fuel; an exhaust path through which flows exhaust gas generated from the combustion of fuel in the combustion device; a dust collection device that is arranged on the exhaust path and collects ash dust/dust in the exhaust gas; and a denitration device that is arranged on the exhaust path and removes nitrogen oxides from the exhaust gas by means of a denitration catalyst, wherein the denitration device is arranged downstream of the dust collection device on the exhaust path, and the denitration catalyst contains vanadium oxide including vanadium pentoxide and has a defect site in which an oxygen atom is deficient in a crystal structure of the vanadium pentoxide.

Abstract: The purpose of the present invention is to provide an injectable sol into a body, suited for delivery through a catheter, and usable for tissue perforation closure, ulcer protection, or vascular embolization. Provided are a sol for tissue perforation closure, a sol for ulcer protection, and a sol for vascular embolization, each containing from 0.6 mass % to 3 mass % of a collagen, water, from 200 mM to 330 mM sodium chloride, and a buffer and having a pH from 6.0 to 9.0.

Abstract: An information acquisition method includes: executing a voxel defining process to divide an area in which a signal source is assumed to be present and define a voxel division V1 specifying resolution of an image; executing a data collecting process to acquire magnetic field data resulting from measurement of a magnetic field generated in the area; and executing a reconstructing process to estimate, by using a mathematical algorithm, a direction and strength of a current of a signal source at a location of each voxel based on the acquired magnetic field data. The reconstructing process includes: calculating a Gram matrix by using a voxel division V2 defined coarser than the voxel division V1; and reconstructing, by using the Gram matrix, a direction and strength of a current of a signal source in the voxel division V1.